Joseph Finkelstein, MD, PhD, is Chief Research Informatics Officer, Senior Associate Dean for Information Technology, and Professor of Population Health and Science at the Icahn School of Medicine at Mount Sinai. Dr. Finkelstein is also the Director of the Center for Biomedical and Population Health informatics and the Associate Director for Cancer Information Technology at The Tisch Cancer Institute, where he leads a core service focused on access to information technology and data analysis for cancer researchers. Dr. Finkelstein has expertise and extensive experience in biomedical informatics with a particular emphasis on innovative health information technologies supporting collection and analysis of heterogeneous data streams, intelligent data aggregation, predictive analysis, and the conduct of clinical trials.
He has made significant contributions to patient-centered health information technologies, interactive patient engagement and empowerment, and home-based telemanagement of chronic health conditions. His research related to cancer care includes interactive tools for patient engagement in cancer prevention and development of harmonized data hubs for predictive cancer analytics.
Dr. Finkelstein serves as Principal Investigator of a nation-wide regenerative medicine data hub aimed at aggregation, harmonization and analysis of clinical trial results assessing stem cell-based therapies funded by NIH as a part of the 21st Century Cures Act. He is also Principal Investigator on NIH grants related to pulmonary rehabilitation and rehabilitation medicine.
Dr. Finkelstein earned his MD and PhD in Medical Cybernetics from Pirogov State Medical University in Moscow. He holds an MA from Biomedical Informatics Columbia University, where he also did post-doctoral training, and he completed a fellowship in Geriatric Medicine and Gerontology at Johns Hopkins University.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Finkelstein did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.